ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2021
Acetazolamide-Associated Acute Kidney Injury in Critically Ill Pediatric Patients.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis.European journal of clinical pharmacology · 2023Pooled it
- Systematic Review of Pharmacologic Treatments for Hypochloremic Metabolic Alkalosis in Critically Ill Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Diazepam exposure associated with an increased risk of acute kidney injury in children: an observational cohort study.BMC pediatrics · 2025Observational
- Beyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Preventing heme-induced nephropathy in children with glucose 6 phosphate dehydrogenase deficiency: is there a role for acetazolamide?Pediatric nephrology (Berlin, Germany) · 2022Article
- Response to the Letter to the Editor "Preventing heme-induced nephropathy in children with glucose 6 phosphate dehydrogenase deficiency: is there a role for acetazolamide?"Pediatric nephrology (Berlin, Germany) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur objective was to determine the incidence and risk factors for intravenous acetazolamide-associated acute kidney injury (AKI).
methodsWe utilized a retrospective cohort study including patients <19 years of age initiated on intravenous acetazolamide while admitted to an ICU. Data collection included patient demographics, clinical variables, acetazolamide dosing, and serum creatinine (SCr) values. Incidence of AKI was assessed per Kidney Disease Improving Global Outcomes criteria. Descriptive statistical analysis and ordinal logistic regression analysis were performed to determine the incidence of AKI and variables associated with AKI.
resultsA total of 868 patients met study criteria (male 55.8%, median age 0.66 years [IQR 0.19, 3.0 years]). Intravenous acetazolamide was administered at 5.1 ± 2.8 mg/kg/dose for a median of 4 doses (IQR 2, 6). Median baseline SCr was 0.28 mg/dL (IQR 0.22, 0.37), corresponding to a creatinine clearance of 115 ± 55 mL/min/1.73 m
conclusionsAcute kidney injury occurs frequently in critically ill pediatric patients receiving intravenous acetazolamide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.